Impact of newborn screening for SCID on the management of congenital athymia
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Newborn screening (NBS) programs for severe combined immunodeficiency facilitate early diagnosis of severe combined immunodeficiency and promote early treatment with hematopoietic stem cell transplantation, resulting in improved clinical outcomes. Infants with congenital athymia are also identified through NBS because of severe T-cell lymphopenia. With the expanding introduction of NBS programs, referrals of athymic patients for treatment with thymus transplantation have recently increased at Great Ormond Street Hospital (GOSH) (London, United Kingdom).
OBJECTIVE: We studied the impact of NBS on timely diagnosis and treatment of athymic infants with thymus transplantation at GOSH.
METHODS: We compared age at referral and complications between athymic infants diagnosed after clinical presentation (n = 25) and infants identified through NBS (n = 19) who were referred for thymus transplantation at GOSH between October 2019 and February 2023. We assessed whether age at time of treatment influences thymic output at 6 and 12 months after transplantation.
RESULTS: The infants referred after identification through NBS were significantly younger and had fewer complications, in particular fewer infections. All deaths occurred in the group of those who did not undergo NBS, including 6 patients before and 2 after thymus transplantation because of preexisting infections. In the absence of significant comorbidities or diagnostic uncertainties, timely treatment was achieved more frequently after NBS. Treatment when younger than age 4 months was associated with higher thymic output at 6 and 12 months after transplantation.
CONCLUSION: NBS contributes to earlier recognition of congenital athymia, promoting referral of athymic patients for thymus transplantation before they acquire infections or other complications and facilitating treatment at a younger age, thus playing an important role in improving their outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:153 |
|---|---|
| Enthalten in: |
The Journal of allergy and clinical immunology - 153(2024), 1 vom: 03. Jan., Seite 330-334 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Howley, Evey [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Athymia |
|---|
| Anmerkungen: |
Date Completed 08.01.2024 Date Revised 17.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaci.2023.08.031 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36176183X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36176183X | ||
| 003 | DE-627 | ||
| 005 | 20240317232922.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaci.2023.08.031 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1333.xml |
| 035 | |a (DE-627)NLM36176183X | ||
| 035 | |a (NLM)37678573 | ||
| 035 | |a (PII)S0091-6749(23)01114-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Howley, Evey |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of newborn screening for SCID on the management of congenital athymia |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.01.2024 | ||
| 500 | |a Date Revised 17.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Newborn screening (NBS) programs for severe combined immunodeficiency facilitate early diagnosis of severe combined immunodeficiency and promote early treatment with hematopoietic stem cell transplantation, resulting in improved clinical outcomes. Infants with congenital athymia are also identified through NBS because of severe T-cell lymphopenia. With the expanding introduction of NBS programs, referrals of athymic patients for treatment with thymus transplantation have recently increased at Great Ormond Street Hospital (GOSH) (London, United Kingdom) | ||
| 520 | |a OBJECTIVE: We studied the impact of NBS on timely diagnosis and treatment of athymic infants with thymus transplantation at GOSH | ||
| 520 | |a METHODS: We compared age at referral and complications between athymic infants diagnosed after clinical presentation (n = 25) and infants identified through NBS (n = 19) who were referred for thymus transplantation at GOSH between October 2019 and February 2023. We assessed whether age at time of treatment influences thymic output at 6 and 12 months after transplantation | ||
| 520 | |a RESULTS: The infants referred after identification through NBS were significantly younger and had fewer complications, in particular fewer infections. All deaths occurred in the group of those who did not undergo NBS, including 6 patients before and 2 after thymus transplantation because of preexisting infections. In the absence of significant comorbidities or diagnostic uncertainties, timely treatment was achieved more frequently after NBS. Treatment when younger than age 4 months was associated with higher thymic output at 6 and 12 months after transplantation | ||
| 520 | |a CONCLUSION: NBS contributes to earlier recognition of congenital athymia, promoting referral of athymic patients for thymus transplantation before they acquire infections or other complications and facilitating treatment at a younger age, thus playing an important role in improving their outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a DiGeorge syndrome | |
| 650 | 4 | |a Thymus transplantation | |
| 650 | 4 | |a athymia | |
| 650 | 4 | |a newborn screening | |
| 650 | 4 | |a severe combined immunodeficiency | |
| 700 | 1 | |a Golwala, Zainab |e verfasserin |4 aut | |
| 700 | 1 | |a Buckland, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Barzaghi, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Ghosh, Sujal |e verfasserin |4 aut | |
| 700 | 1 | |a Hackett, Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Hague, Rosie |e verfasserin |4 aut | |
| 700 | 1 | |a Hauck, Fabian |e verfasserin |4 aut | |
| 700 | 1 | |a Holzer, Ursula |e verfasserin |4 aut | |
| 700 | 1 | |a Klocperk, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Koskenvuo, Minna |e verfasserin |4 aut | |
| 700 | 1 | |a Marcus, Nufar |e verfasserin |4 aut | |
| 700 | 1 | |a Marzollo, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Pac, Malgorzata |e verfasserin |4 aut | |
| 700 | 1 | |a Sinclair, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Speckmann, Carsten |e verfasserin |4 aut | |
| 700 | 1 | |a Soomann, Maarja |e verfasserin |4 aut | |
| 700 | 1 | |a Speirs, Lynne |e verfasserin |4 aut | |
| 700 | 1 | |a Suresh, Sneha |e verfasserin |4 aut | |
| 700 | 1 | |a Taque, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a van Montfrans, Joris |e verfasserin |4 aut | |
| 700 | 1 | |a von Bernuth, Horst |e verfasserin |4 aut | |
| 700 | 1 | |a Wainstein, Brynn K |e verfasserin |4 aut | |
| 700 | 1 | |a Worth, Austen |e verfasserin |4 aut | |
| 700 | 1 | |a Davies, E Graham |e verfasserin |4 aut | |
| 700 | 1 | |a Kreins, Alexandra Y |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of allergy and clinical immunology |d 1971 |g 153(2024), 1 vom: 03. Jan., Seite 330-334 |w (DE-627)NLM000018449 |x 1097-6825 |7 nnns |
| 773 | 1 | 8 | |g volume:153 |g year:2024 |g number:1 |g day:03 |g month:01 |g pages:330-334 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaci.2023.08.031 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 153 |j 2024 |e 1 |b 03 |c 01 |h 330-334 | ||